BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bader RM, Jonas MM, Mitchell PD, Wiggins S, Lee CK. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. J Cyst Fibros. 2019;18:280-285. [PMID: 30509601 DOI: 10.1016/j.jcf.2018.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 2. Pediatr Pulmonol 2019;54:1129-40. [PMID: 31125191 DOI: 10.1002/ppul.24365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ye W, Leung DH, Molleston JP, Ling SC, Murray KF, Nicholas JL, Huang S, Karmazyn BW, Harned RK, Masand P, Alazraki AL, Navarro OM, Otto RK, Palermo JJ, Towbin AJ, Alonso EM, Karnsakul WW, Jane Schwarzenberg S, Seidel GF, Siegel M, Magee JC, Narkewicz MR, Jay Freeman A. Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis. Hepatol Commun 2021;5:1362-72. [PMID: 34430781 DOI: 10.1002/hep4.1719] [Reference Citation Analysis]
3 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Masand PM, Narkewicz MR, Leung DH. The Emergence of Elastography for Cystic Fibrosis Liver Disease. J Cyst Fibros 2020;19:339-41. [PMID: 32600654 DOI: 10.1016/j.jcf.2020.06.006] [Reference Citation Analysis]